Stock Events

Stock Events

Gilead Sciences 

€149.78
2898
+€0.86+0.58%Friday 20:55

Statistics

Day High
151.18
Day Low
146.12
52W High
156.64
52W Low
99.98
Volume
802
Avg. Volume
-
Mkt Cap
185.78B
P/E Ratio
-
Dividend Yield
1.95%
Dividend
2.92

Upcoming

Dividends

1.95%Dividend Yield
Sep 2026
€0.72
Jun 2026
€0.72
Mar 2026
€0.72
Dec 2025
€0.67
Sep 2025
€0.67
10Y Growth
5.77%
5Y Growth
3.63%
3Y Growth
0.68%
1Y Growth
0.47%

Earnings

Oct 29Expected
Q2 2025
Q4 2025
Q2 2026
Q3 2026
-6.28
-3.43
-0.57
2.28
Expected EPS
1.95955706186
Actual EPS
2.280363

Financials

28.73%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
25.54BRevenue
7.34BNet Income

Analyst Ratings

$131.37Average Price Target
The highest estimate is ⁦151.76⁩.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GIS.STU. It's not an investment recommendation.
Apple
608
AAPL
Realty Income
585
O
Abbvie
584
ABBV
Microsoft
579
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes directly with Gilead in the areas of hepatitis C treatments and is also a major player in immunology and oncology.
Merck
MRK
Mkt Cap368.89B
Merck & Co. offers competitive products in the antiviral space, including treatments for HIV and hepatitis C, directly challenging Gilead's core market.
Pfizer
PFE
Mkt Cap173.95B
Pfizer competes across several therapeutic areas including oncology, immunology, and antiviral drugs, overlapping with Gilead's product portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb is a key competitor in the oncology and immunology sectors, areas where Gilead Sciences is actively expanding its presence.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the HIV and hepatitis C markets, among others, where Gilead has significant interests.
AMGEN
AMGN
Mkt Cap251.94B
Amgen competes with Gilead in the biopharmaceutical space, particularly in the areas of oncology and inflammatory diseases.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline, through its ViiV Healthcare joint venture, is a strong competitor in the HIV treatment market, directly challenging Gilead's leadership.
Novartis
NVS
Mkt Cap303.67B
Novartis competes with Gilead in several areas including oncology and gene therapy, with both companies investing heavily in research and development.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech unit, competes in the oncology and antiviral markets, areas where Gilead has key products.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca competes with Gilead in the oncology sector, with both companies developing treatments for various cancers.

About

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Show More
CEO
Daniel O'Day
Employees
17000
Country
United States
ISIN
US3755581036
WKN
000885823

Listings

BOATS
BOATS
GILD.BOATS
F
DE
GIS.F
SN
CL
GILDCL.SN
LSE
GB
0QYQ.LSE

0 Comments

Share your thoughts

FAQs

What is Gilead Sciences stock price today?▼
The current price of GIS.STU is €149.78 EUR — it has increased by +0.58% in the past 24 hours. Watch Gilead Sciences stock price performance more closely on the chart.
What is Gilead Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Gilead Sciences stocks are traded under the ticker GIS.STU.
Is Gilead Sciences stock price growing?▼
GIS.STU stock has fallen by -1.91% compared to the previous week, the month change is a +14.14% rise, over the last year Gilead Sciences has showed a +44.74% increase.
What is Gilead Sciences market cap?▼
Today Gilead Sciences has the market capitalization of 185.78B
When is the next Gilead Sciences earnings date?▼
Gilead Sciences is going to release the next earnings report on March 3, 2027.
What were Gilead Sciences earnings last quarter?▼
GIS.STU earnings for the last quarter are 2.28 EUR per share, whereas the estimation was 1.96 EUR resulting in a +16.37% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Gilead Sciences revenue for the last year?▼
Gilead Sciences revenue for the last year amounts to 25.54B EUR.
What is Gilead Sciences net income for the last year?▼
GIS.STU net income for the last year is 7.34B EUR.
Does Gilead Sciences pay dividends?▼
Yes, GIS.STU dividends are paid quarterly. The last dividend per share was 0.72 . As of today, Dividend Yield (FWD)% is 1.95%.
How many employees does Gilead Sciences have?▼
As of November 7, 2026, the company has 17,000 employees.
In which sector is Gilead Sciences located?▼
Gilead Sciences operates in the Health & Wellness sector.
When did Gilead Sciences complete a stock split?▼
The last stock split for Gilead Sciences was on January 28, 2013 with a ratio of 2:1.
Where is Gilead Sciences headquartered?▼
Gilead Sciences is headquartered in FOSTER CITY, United States.